Overview

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

Status:
Terminated
Trial end date:
2017-02-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) as a method to increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within or between collagen fibers using UVA light and the photo- mediator riboflavin. The purpose of this study is to generate data for presentation at medical meetings and for peer-review publication. The data generated by this study will not be submitted to the FDA to support commercialization of these riboflavin drops.
Details
Lead Sponsor:
Cxlusa
Treatments:
Bromfenac
Diclofenac
Fluorometholone
Ketorolac
Ketorolac Tromethamine
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate